website2646
- Aug 17, 2022
- 1 min read

BMS acquisition of Turning Point Therapeutics at US$4.1 B closed on 8/15/2022

https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-and-Turning-Point-Therapeutics-Announce-Expiration-of-HSR-Act-Waiting-Period-and-Clearance-from-Federal-Cartel-Office-of-Germany-Related-to-Pending-Acquisition-of-Turning-Point-Therapeutics/default.aspx

Recent Posts

See All

The Top 3 Future Foods at CES 2023

The Top 3 Future Foods I Tasted At CES 2023 (greenqueen.com.hk)

Eureka Therapeutics is selected 2022 Red Herring Top 100 Global Winners

https://smex-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fwww.redherring.com%2fevents%2fred%2dherring%2dglobal%2f2022%2dred%2dherring%2dtop%2d100%2dglobal%2dwinners%2f&umid=a90cffe6

〈視陽光學轉上市〉檳城廠持續擴充明年Q2月產能上看3800萬片增逾2成

https://news.cnyes.com/news/id/4988977?utm_campaign=share_button&utm_medium=news_article&utm_source=cnyesnewsapp

Venture Capital

聯訊創投

BMS acquisition of Turning Point Therapeutics at US$4.1 B closed on 8/15/2022

Recent Posts

Harbinger Venture Capital